214 related articles for article (PubMed ID: 33653952)
1. Mesoscopic protein-rich clusters host the nucleation of mutant p53 amyloid fibrils.
Yang DS; Saeedi A; Davtyan A; Fathi M; Sherman MB; Safari MS; Klindziuk A; Barton MC; Varadarajan N; Kolomeisky AB; Vekilov PG
Proc Natl Acad Sci U S A; 2021 Mar; 118(10):. PubMed ID: 33653952
[TBL] [Abstract][Full Text] [Related]
2. Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer.
Ano Bom AP; Rangel LP; Costa DC; de Oliveira GA; Sanches D; Braga CA; Gava LM; Ramos CH; Cepeda AO; Stumbo AC; De Moura Gallo CV; Cordeiro Y; Silva JL
J Biol Chem; 2012 Aug; 287(33):28152-62. PubMed ID: 22715097
[TBL] [Abstract][Full Text] [Related]
3. Disruption of an intermonomer salt bridge in the p53 tetramerization domain results in an increased propensity to form amyloid fibrils.
Galea C; Bowman P; Kriwacki RW
Protein Sci; 2005 Dec; 14(12):2993-3003. PubMed ID: 16260757
[TBL] [Abstract][Full Text] [Related]
4. Unfolding, aggregation, and amyloid formation by the tetramerization domain from mutant p53 associated with lung cancer.
Higashimoto Y; Asanomi Y; Takakusagi S; Lewis MS; Uosaki K; Durell SR; Anderson CW; Appella E; Sakaguchi K
Biochemistry; 2006 Feb; 45(6):1608-19. PubMed ID: 16460008
[TBL] [Abstract][Full Text] [Related]
5. Anomalous Dense Liquid Condensates Host the Nucleation of Tumor Suppressor p53 Fibrils.
Safari MS; Wang Z; Tailor K; Kolomeisky AB; Conrad JC; Vekilov PG
iScience; 2019 Feb; 12():342-355. PubMed ID: 30739016
[TBL] [Abstract][Full Text] [Related]
6. Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor.
Silva JL; Rangel LP; Costa DC; Cordeiro Y; De Moura Gallo CV
Biosci Rep; 2013 Jul; 33(4):. PubMed ID: 24003888
[TBL] [Abstract][Full Text] [Related]
7. Reversible amyloid formation by the p53 tetramerization domain and a cancer-associated mutant.
Lee AS; Galea C; DiGiammarino EL; Jun B; Murti G; Ribeiro RC; Zambetti G; Schultz CP; Kriwacki RW
J Mol Biol; 2003 Mar; 327(3):699-709. PubMed ID: 12634062
[TBL] [Abstract][Full Text] [Related]
8. Polymorphism of Lysozyme Condensates.
Safari MS; Byington MC; Conrad JC; Vekilov PG
J Phys Chem B; 2017 Oct; 121(39):9091-9101. PubMed ID: 28881129
[TBL] [Abstract][Full Text] [Related]
9. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
10. Amyloidogenicity of p53: a hidden link between protein misfolding and cancer.
Gong H; Yang X; Zhao Y; Petersen RB; Liu X; Liu Y; Huang K
Curr Protein Pept Sci; 2015; 16(2):135-46. PubMed ID: 25692950
[TBL] [Abstract][Full Text] [Related]
11. Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity.
Lasagna-Reeves CA; Clos AL; Castillo-Carranza D; Sengupta U; Guerrero-Muñoz M; Kelly B; Wagner R; Kayed R
Biochem Biophys Res Commun; 2013 Jan; 430(3):963-8. PubMed ID: 23261448
[TBL] [Abstract][Full Text] [Related]
12. Modulation of p53 and prion protein aggregation by RNA.
Cordeiro Y; Vieira T; Kovachev PS; Sanyal S; Silva JL
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):933-940. PubMed ID: 30826454
[TBL] [Abstract][Full Text] [Related]
13. Fluorescent Biosensor for Detection of the R248Q Aggregation-Prone Mutant of p53.
Pellerano M; Naud-Martin D; Mahuteau-Betzer F; Morille M; Morris MC
Chembiochem; 2019 Feb; 20(4):605-613. PubMed ID: 30548750
[TBL] [Abstract][Full Text] [Related]
14. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
15. Structures of oncogenic, suppressor and rescued p53 core-domain variants: mechanisms of mutant p53 rescue.
Wallentine BD; Wang Y; Tretyachenko-Ladokhina V; Tan M; Senear DF; Luecke H
Acta Crystallogr D Biol Crystallogr; 2013 Oct; 69(Pt 10):2146-56. PubMed ID: 24100332
[TBL] [Abstract][Full Text] [Related]
16. Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function.
Palanikumar L; Karpauskaite L; Al-Sayegh M; Chehade I; Alam M; Hassan S; Maity D; Ali L; Kalmouni M; Hunashal Y; Ahmed J; Houhou T; Karapetyan S; Falls Z; Samudrala R; Pasricha R; Esposito G; Afzal AJ; Hamilton AD; Kumar S; Magzoub M
Nat Commun; 2021 Jun; 12(1):3962. PubMed ID: 34172723
[TBL] [Abstract][Full Text] [Related]
17. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.
Conway KA; Harper JD; Lansbury PT
Biochemistry; 2000 Mar; 39(10):2552-63. PubMed ID: 10704204
[TBL] [Abstract][Full Text] [Related]
18. Amyloid Evolvability and Cancer.
Takamatsu Y; Ho G; Hashimoto M
Trends Cancer; 2020 Aug; 6(8):624-627. PubMed ID: 32386876
[TBL] [Abstract][Full Text] [Related]
19. The Prenucleation Equilibrium of the Parathyroid Hormone Determines the Critical Aggregation Concentration and Amyloid Fibril Nucleation.
Voigt B; Bhatia T; Hesselbarth J; Baumann M; Schmidt C; Ott M; Balbach J
Chemphyschem; 2023 Oct; 24(19):e202300439. PubMed ID: 37477386
[TBL] [Abstract][Full Text] [Related]
20. Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors.
Levy CB; Stumbo AC; Ano Bom AP; Portari EA; Cordeiro Y; Silva JL; De Moura-Gallo CV
Int J Biochem Cell Biol; 2011 Jan; 43(1):60-4. PubMed ID: 21056685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]